Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01), Bloomberg Earnings reports. Capricor Therapeutics had a negative return on equity of 204.82% and a net margin of 111.24%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.90 million.
Shares of CAPR traded down $0.01 during trading hours on Wednesday, hitting $0.89. The stock had a trading volume of 90,019 shares, compared to its average volume of 176,624. Capricor Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.94. The firm has a market capitalization of $28.71 million, a P/E ratio of -2.02 and a beta of -2.24.
CAPR has been the subject of several research analyst reports. Maxim Group set a $4.00 price objective on Capricor Therapeutics and gave the stock a “buy” rating in a report on Wednesday. TheStreet lowered Capricor Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, October 15th. Finally, Zacks Investment Research raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.83.
ILLEGAL ACTIVITY NOTICE: “Capricor Therapeutics (CAPR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS” was first posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://macondaily.com/2018/11/14/capricor-therapeutics-capr-releases-quarterly-earnings-results-misses-expectations-by-0-01-eps.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Article: Why do companies engage in swaps?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.